Stockscreener 앱 받기
27.44
0.73%
0.20
시간 외 거래:
26.73
-0.71
-2.59%
전일 마감가:
$27.24
열려 있는:
$27.25
하루 거래량:
945.89K
Relative Volume:
1.51
시가총액:
$2.17B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-196.00
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
-3.31%
1개월 성능:
-1.72%
6개월 성능:
+37.61%
1년 성능:
+48.73%
1일 변동 폭
$26.89
$27.97
1주일 범위
$26.89
$28.86
52주 변동 폭
$17.82
$30.69
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
27.44 | 2.17B | 384.10M | -9.07M | 11.10M | -0.14 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa pharma COO Tessari sells $489k in shares By Investing.com - Investing.com South Africa
Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 17,300 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA) - Seeking Alpha
Lewis & Ellis acquires Huggins Actuarial Services - Yahoo
UK court rules insurers must pay more than $1bn for planes seized in Russia - Yahoo
Payment software firm Payrails raises $32m in funding - Yahoo
WRAP EU leads textiles extended producer responsibility talks - Yahoo
Canary raises $80m to fuel expansion in hospitality AI - Yahoo
FirmaPak expands global footprint with Lighthouse Packaging acquisition - Yahoo
FDA approves label expansion of AbbVie hepatitis C therapy - Yahoo
Israel attacks Iran, stock market futures tumble - Yahoo
Green Bay Packaging Executive Vice President Bryan Hollenbach to retire in August - Yahoo
Jio BlackRock gets nod to operate as investment adviser in India - Yahoo
Output of key food commodities “on course for new records” – FAO - Yahoo
Why Oklo Stock Dropped on Thursday - Yahoo
Medtech leaders unite on Capitol Hill to fight tariffs - Yahoo
Actabl launches new ProfitSword digital night audit feature for hotels - Yahoo
UCC Holding and Ashghal launch 3D Printed Schools Project in Qatar - Yahoo
Grant Thornton Advisors appoints new COO - Yahoo
Biggby Coffee unveils first brand refresh - Yahoo
Prime Drink Group’s bottling unit enters receivership - Yahoo
Del Taco expands to Louisville with new franchise agreement - Yahoo
Trump’s Treasury Sec Admits It’s Another TACO Day With China - Yahoo
Hakkers and Paebbl introduce carbon-storing solution at Port of Rotterdam - Yahoo
Mistral unveils Europe’s first AI reasoning model Magistral - Yahoo
Costco Announces Important Change for Certain Members Starting June 30 - Yahoo
Transcript : Kiniksa Pharmaceuticals International, plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
MSD receives FDA approval for Enflonsia to prevent RSV - Yahoo
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
KNSA stock soars to 52-week high, hits $29.71 amid robust gains - Investing.com UK
Kiniksa sets Phase 2/3 trial for heart drug KPL-387 - Investing.com Nigeria
Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | K - GuruFocus
Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis - marketscreener.com
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | KNSA Stock News - GuruFocus
Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | KNSA Stock News - GuruFocus
Kiniksa Pharmaceuticals Announces Trial Design of Planned - GlobeNewswire
Kiniksa Advances Revolutionary Monthly Dosing Treatment for Recurrent Pericarditis: Phase 2/3 Trial Details Released - Stock Titan
Louis Vuitton files lawsuit against Portuguese liqueur start-up over branding rights - Yahoo
Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions - TipRanks
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire
Kiniksa Pharmaceuticals to Present at Jefferies and Goldman Sachs Healthcare Conferences in June - Stock Titan
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 4.13% H - GuruFocus
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 4.13% Higher on May 28 - GuruFocus
Beloved Fast Food Chain Makes Telling Move After Closing Hundreds of Locations - Yahoo
Okika Devices relocates HQ to Colorado Springs - Yahoo
Maryland loses Triple-A bond rating - Yahoo
Dimensional Fund Advisors LP Acquires 29,300 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals CEO sells shares worth $218,866 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CEO sells shares worth $218,866 - Investing.com Australia
Capra Bank recognized as fastest growing in recent study - Yahoo
Kiniksa Pharmaceuticals: Making Steady Progress (NASDAQ:KNSA) - Seeking Alpha
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kiniksa Pharmaceuticals International Plc 주식 (KNSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tessari Eben | CHIEF OPERATING OFFICER |
Jun 16 '25 |
Sale |
28.28 |
17,300 |
489,244 |
61,563 |
2.01%
0.40%
자본화:
|
볼륨(24시간):